Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 R683G JAK2 L884P |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK2 R683G JAK2 L884P | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited viability of a cell line expressing JAK2 R683G and L884P in culture (PMID: 37290440). | 37290440 | |
JAK2 R683G JAK2 L884P | Advanced Solid Tumor | sensitive | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Inrebic (fedratinib) inhibited viability of a cell line expressing JAK2 R683G and L884P in culture (PMID: 37290440). | 37290440 | |
JAK2 R683G JAK2 L884P | Advanced Solid Tumor | resistant | CHZ868 | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 R683G and L884P was resistant to CHZ868 in culture (PMID: 37290440). | 37290440 |